interview

Marco Cavaleri, injecting injection vaccine vaccination medicine flu woman doctor

A scientist’s opinion : Interview with Marco Cavaleri about vaccine procedure

Marco Cavaleri is Head of Office, Biological Health Threats and Vaccines Strategy at the European Medicines Agency (EMA). He is also the chair of the COVID-19 EMA pandemic Task Force and is responsible for EMA activities regarding emerging pathogens, vaccines and antimicrobial resistance. He is a pharmacologist who has spent several years in industry in ...

Prof Cristina Mussini, Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Prof Cristina Mussini about covid-19 treatment

Interview with Professor Cristina Mussini, Head of the Department of Infectious Diseases and Tropical Medicine at the University of Modena and Reggio Emilia in Italy and member of the European AIDS Clinical Society. She has been actively involved in various recent studies on the clinical use of tocilizumab in patients with COVID-19 pneumonia. First a ...

Dr Andrew Ip, Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Dr Andrew Ip about covid-19 treatment

Interview with Dr Andrew Ip, a specialist in hematology/oncology at the John Theurer Cancer Center at Hackensack University Medical Center, USA, who has been involved in research on tocilizumab use in COVID-19 patients. Why did you choose tocilizumab to treat patients with COVID-19 pneumonia? Andrew Ip: Tocilizumab is a monoclonal antibody that inhibits the interleukin-6 ...

Dr Juan Victor San-Martin Lopez, Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Dr Juan Victor San-Martin Lopez about covid-19 treatment

Interview with Dr Juan Victor San-Martín López, a physician specialising in infectious diseases and a member of the task force coordinating responses to the leishmaniasis outbreak in 2011 and to COVID-19 at the Hospital Universitario de Fuenlabrada, Spain. He reports on his experience with tocilizumab use in COVID-19 patients. What is the so-called cytokine storm? ...

Prof Martijn van Hemert, Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Prof Martijn van Hemert about covid-19 treatment

Interview with Martijn van Hemert, Associate professor and Principal Investigator in molecular virology and antiviral strategies at the Leiden University Medical Center. In recent years, his group has mainly been studying the Chikungunya and Zika viruses, but in the past he has also studied SARS-CoV. Since February 2020, he has shifted his focus to research ...

Dr Juan Pablo Horcajada, Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Dr Juan Pablo Horcajada about covid-19 treatment

Interview with Juan Pablo Horcajada, MD. is Head of the Department of Infectious Diseases and General Coordinator of the COVID-19 Service at the Hospital del Mar, Barcelona. Remdesivir is the first drug approved by the EMA to be used as part of the treatment of COVID-19 patients. How’s the use of this antiviral in your ...

Sarah Diefenbach, Online video guided yoga

A scientist’s opinion : Interview with Prof Sarah Diefenbach about digital well-being

Interview with Sarah Diefenbach, Professor of Marketing and Consumer Psychology at the Ludwig Maximilian University of Munich, German. What does your research investigate exactly? Sarah Diefenbach: In general, my research is centred on digital products from a psychological perspective. On the one hand, this includes the application of psychological knowledge (“psychological needs frameworks”, for example) ...

James Dennis, Online video guided yoga

A scientist’s opinion : Interview with Matthew James Dennis about digital well-being

Interview with Matthew James Dennis, ethicist of emerging technologies at Marie Sklodowska-Curie Research Fellow at Delft University of Technology, the Netherlands. What is the focus of your research? Matthew James Dennis: My main research question concerns how we can live well with technology, especially new and emerging online technologies. Basically, I’m interested in the extent ...